Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s00739-020-00691-z http://scihub22266oqcxt.onion/10.1007/s00739-020-00691-z C7809639/?report=reader!7809639!C7809639     free     free     free       ä-/-ä 2021 ; 24 (2): 98-101 Nephropedia Template TP {{tp|p=C7809639|t=2021. Multiple Sklerose und COVID-19 |pdf=|usr=}}{{C7809639}} gab.com Text Multiple Sklerose und COVID-19 JO: ä-/-ä http://www.kidney.de/pget.php?&tw=1&pmid=C7809639 #FOAvip Age, higher EDSS (Expanded Disability Status Scale), obesity and comorbidities are known risk factors for severe course of COVID-19 in patients with multiple sclerosis. However, multiple sclerosis per se is not an isolated factor for higher risk of infection with SARS-CoV?2 or severe course. So far disease-modifying therapy prevalence has not shown a difference in clinical outcome compared to patients without multiple sclerosis, but further confirmation is warranted. Treatment for multiple sclerosis should be continued despite the COVID-19 pandemic. In patients with appropriate indications, initiation of treatment should not be delayed. More analyses of future registry data to confirm the previous observations is desirable and necessary. Twit Text FOAVip Multiple Sklerose und COVID-19 ????ä-/-ä http://www.kidney.de/pget.php?&tw=1&pmid=C7809639 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=C7809639 #FOAvip English Wikipedia <ref>{{Cite pmid|C7809639}}</ref> Multiple Sklerose und COVID-19 #MMPMIDC7809639 Guger M; Traxler G ä-/-ä 2021[]; 24 (2): 98-101 PMIDC7809639show ga Age, higher EDSS (Expanded Disability Status Scale), obesity and comorbidities are known risk factors for severe course of COVID-19 in patients with multiple sclerosis. However, multiple sclerosis per se is not an isolated factor for higher risk of infection with SARS-CoV?2 or severe course. So far disease-modifying therapy prevalence has not shown a difference in clinical outcome compared to patients without multiple sclerosis, but further confirmation is warranted. Treatment for multiple sclerosis should be continued despite the COVID-19 pandemic. In patients with appropriate indications, initiation of treatment should not be delayed. More analyses of future registry data to confirm the previous observations is desirable and necessary. äMultiple Sklerose und COVID-19 (epmc).pdf DeepDyve Pubget Overpricing